Reversible severe mitral regurgitation during immunotherapy in a structurally vulnerable valve: a case report
{{output}}
Background: T-cell therapy (TCT) rarely causes isolated severe valvular pathology without cardiomyopathy, but its haemodynamic effects can exacerbate mitral regurgitation (MR) in patients with subtle valvular issues, and reports ... ...
